Triplet therapies including a mutation agnostic agent (e.g., those incorporating a CD123-directed therapy [106] or a purine analog [102]) may be of interest in challenging subsets such as TP53 mutated AML. The gene discussed is TP53; the disease is acute myeloid leukemia.